Scientific Finding: EGFR is target for Chemotherapy

December 05, 2020

Los Angeles, CA (USC-Keck School of MedicineOriginal Article) April 5th, 2009

Abstract: The epidermal growth factor receptor (EGFR) is overexpressed in as many as 77% of colorectal cancer (CRC) cases. The EGFR is known to be involved in carcinogenetic processes such as cell proliferation, apoptosis, angiogenesis, cell motility, and metastasis. Preclinical and clinical studies have shown that targeting EGFR is a valid strategy for anticancer therapy. Currently, 2 classes of anti-EGFR agents are in phase II/III clinical development: monoclonal antibodies and tyrosine kinase (TK) inhibitors. The most established monoclonal antibody is cetuximab, the only EGFR inhibitor that is currently approved for use in patients with metastatic CRC. Several clinical studies of cetuximab, as a single agent or in combination with irinotecan, have shown promising efficacy in patients with metastatic CRC. READ MORE

published April 5th, 2005




Also in News

Understanding Alcohol in Skincare. Not all alcohols are what you may think.

July 28, 2021

When we hear, "alcohol" most people think of rubbing alcohol (isopropyl) or alcoholic beverages (ethanol).  When employed in personal care products, it is often erroneously assumed that all alcohols are drying to the skin.

Read More

Eye melanoma risk factors

December 07, 2020

Read More

Some Women’s Preventive Services Now Covered Without Co-Payment

December 07, 2020

Read More